The Cigna Group
CI: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$133.00 | Zmqmzy | Jmfnrzqj |
Cigna Turns in Solid Q4 and 2023 Guidance; No Fair Value Estimate Change
Narrow-moat Cigna turned in strong fourth-quarter results that allowed the firm to exceed our expectations for 2022 a bit. However, that mild outperformance combined with 2023 guidance that looks roughly in line with our expectations was not enough to change our $321 fair value estimate. Shares appear about fairly valued, to us.